Associated tags: Medicine, OGM, Patient, Spectrum, Biology, Genome, Software, SAN, Genomics, Doctor of Philosophy, Research
Locations: SWITZERLAND, MASSACHUSETTS, HAMILTON, NEVADA, LONG, UNITED STATES, UKRAINE, RUSSIA, GEORGIA, SPAIN, LOS ANGELES, RENO, NEW YORK CITY, ISRAEL, SAN DIEGO, CA, US, BEIJING, NEW YORK, CHINA, FLORIDA
CMA,
OGM,
SVS,
Bone marrow,
Workflow,
WHO,
NCCN,
Blood,
SAN,
IRB,
Laboratory,
University,
LDT,
Aberration,
VAF,
World Health Organization,
Genome,
National Comprehensive Cancer Network,
Chromosomal translocation,
Tier 1,
KT,
Diagnosis,
Patient,
Malignancy,
Tier 2 SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne.
Key Points:
- SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne.
- The publication also included a multi-site peer-reviewed IRB-approved analytical validation study of OGM for the analysis of hematological malignancy samples, conducted by researchers at laboratories including Bionano Laboratories, Augusta University, University of Rochester Medical Center, and Children’s Hospital Los Angeles.
- Subsequently, the OGM workflow was applied at the other three sites, showing high levels of reproducibility across the sites.
- “We are pleased to see the clinical validation of Bionano Laboratories' OGM-Dx™ HemeOne LDT, analyzing its potential to serve as a first-tier cytogenetic test for heme malignancies.
Acute lymphoblastic leukemia,
SVS,
OGM,
University Medical Center,
Research,
Leukemia,
Hematology,
Bone marrow,
Multiple myeloma,
SAN,
Society,
MDS,
ASH,
B cell,
Annual general meeting,
Syndrome,
ALL ASH’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in the field of blood disease.
Key Points:
- ASH’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in the field of blood disease.
- The ASH conference will be held December 9-12, 2023, in San Diego, California and online.
- 13 posters featuring results from OGM applications in cytogenetic research will be presented at the conference.
- Unless otherwise noted below, posters will be available to view at the Manchester Grand Hyatt Harbor Ballroom.
NGS,
SMCHD1,
OGM,
Facioscapulohumeral muscular dystrophy,
SAN,
FSHD,
LDT,
Mosaic,
Laboratory,
Leiden University Medical Center,
Bombay Hospital,
Diagnosis The study authors assessed the yield of OGM for diagnosing FSHD1 and the ability of next generation sequencing (NGS) to be used as a reflex test to identify FSHD2.
Key Points:
- The study authors assessed the yield of OGM for diagnosing FSHD1 and the ability of next generation sequencing (NGS) to be used as a reflex test to identify FSHD2.
- The study, which included 547 cases with a clinical suspicion of FSHD, used an algorithm that utilized OGM to identify the FSHD haplotype and quantitate the number of D4Z4 repeats found on chromosome 4.
- “Bionano Laboratories has developed a powerful menu of OGM-based LDTs, including one LDT for FSHD1 diagnosis.
- We are pleased to see this prestigious group of researchers’ findings from the largest FSHD study to date utilizing OGM.
Gene editing,
CD40LG,
SVS,
OGM,
CRISPR,
Quality control,
SAN,
Doctor of Philosophy,
PCR,
DdPCR,
Cancer,
Genomics,
Infection,
Cell,
Liver disease The study authors first validated OGM’s performance at high coverage to capture unexpected gene editing events and found that it outperformed karyotyping’s resolution and sensitivity.
Key Points:
- The study authors first validated OGM’s performance at high coverage to capture unexpected gene editing events and found that it outperformed karyotyping’s resolution and sensitivity.
- OGM then revealed the presence of concameters missed by the ddPCR assay, indicating that 20-50% of the edited cells expressing the rescued gene did not undergo precise editing.
- In addition, OGM detected 11 nonrecurring SVs outside of the target locus, demonstrating its genome-wide ability to detect off-target events.
- The expansion of gene therapy faces risks due to both on-target and off-target structural variations that may be introduced during CRISPR-Cas9 genome editing.
TSLA,
Carnegie Mellon University,
Entropic Communications,
Organization,
CFO,
Industrial,
Information technology,
University,
Qualcomm,
Business administration,
Financial management,
Growth,
ADAS,
Tesla, Inc.,
TM Capital Corp.,
Security (finance),
Management,
Cayman Islands QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech ®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer (“CFO”).
Key Points:
- QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech ®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer (“CFO”).
- Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies.
- In addition, Mr. Stewart held multiple leadership roles, including Vice President of Finance at Entropic Communications and Chief Financial Officer of V-ENABLE Inc. (currently GroundTruth), a leader in targeted mobile advertising.
- I am extremely energized by LeddarTech’s accomplishments and look forward to helping it realize all of its potential.”
Mr. Charles Boulanger, CEO of LeddarTech, commented: “I am very pleased that Chris has joined the executive team of LeddarTech as Chief Financial Officer.
CNS,
Research,
Bone marrow,
SAN,
OGM,
University,
Hospital,
Scalability,
B-cell lymphoma,
Expo Hall,
Genomics,
Second Level Address Translation,
CD5,
Laboratory,
Neoplasm,
Crocker,
Ravindra and Smita Kolhe,
Workflow,
DSM-IV codes,
SVS,
Convention center,
Greater Columbus Convention Center,
Cancer,
Mapping,
Central nervous system,
MD Anderson Cancer Center,
AMP,
Medical device,
Vaccine,
DRS,
Adult,
Brigham AMP’s annual meeting brings together industry, medical, and academic professionals to discuss advances in molecular diagnostics.
Key Points:
- AMP’s annual meeting brings together industry, medical, and academic professionals to discuss advances in molecular diagnostics.
- The presenters will share data on OGM’s performance in this research application as compared to traditional cytogenetic methods of analysis, including microarrays.
- Ryall, Dubuc and Crocker presenting clinical research data generated using OGM across different types of hematological malignancies.
- In addition, 19 posters featuring results from OGM applications in cytogenetic research will be presented at the conference.
Spectrum,
German Cancer Research Center,
Aneuploidy,
CMA,
MCA,
OEM,
Sale,
Genomics,
DSM-IV codes,
OGM,
NMPA,
WES,
SVS,
IVD,
Publication,
Rare,
Polyploidy,
CRISPR,
Medtech,
International Cancer Genome Consortium,
Doctor of Philosophy,
GAAP,
Acquisition,
Research,
Poster,
Karyotype,
Lobotomy Corporation,
Genome,
Nature Communications,
National Medical Products Administration,
SNV calling from NGS data,
Hospital,
Annual general meeting,
CGC,
Workflow,
Bone marrow,
KT,
CFO,
Cancer,
ASD,
Total,
VIA,
IPSC,
Chromosomal deletion syndrome,
SAN,
DNA,
Outline,
Beauty salon,
Cryptocurrency,
Video game,
Vaccine,
Management,
Medical device,
Pharmaceutical industry Publications featuring OGM increased 61% from the third quarter of 2022 to the third quarter of 2023, including a total of 47 human-focused publications.
Key Points:
- Publications featuring OGM increased 61% from the third quarter of 2022 to the third quarter of 2023, including a total of 47 human-focused publications.
- GAAP gross margin for the third quarter of 2023 was 30%, compared to 25% from the third quarter of 2022.
- Third quarter 2023 non-GAAP¹ gross margin was 32%, compared to 25% from the third quarter of 2022.
- Third quarter 2023 non-GAAP operating expense was $31.8 million, compared to $26.3 million in the third quarter of 2022 and $34.6 million in the second quarter of 2023.
Genetic counseling,
Medical genetics,
OGM,
SVS,
Genetics,
American Board of Commissioners for Foreign Missions,
Doctor of Philosophy,
LRS,
FACMG,
DSM-IV codes,
Student,
Textbook,
SAN,
Antibiotics,
Genomics,
Medicine The publication, which was last updated in 2015, includes information on new discoveries in the fields of genetics and genomics, the latest technologies in genome analysis, and new diagnoses these methods can enable.
Key Points:
- The publication, which was last updated in 2015, includes information on new discoveries in the fields of genetics and genomics, the latest technologies in genome analysis, and new diagnoses these methods can enable.
- The book’s authors describe OGM as a powerful tool for genome analysis, due to its ability to detect and validate structural variants (SVs) that sequencing techniques may miss.
- They also note that, when compared to long-read sequencing (LRS), OGM can be less expensive and can resolve complex SVs with greater precision, showing its potential as a tool in clinical research investigations.
- “We are thrilled to see OGM included in the newest edition of Thompson and Thompson Genetics and Genomics in Medicine, which is the primary training manual for trainees and fellows seeking ABMGG certifications in clinical biochemical genetics, laboratory genetics and genomics, and clinical molecular genetics.
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at 2023 Stifel Healthcare Conference on November 15, 2023.
Key Points:
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at 2023 Stifel Healthcare Conference on November 15, 2023.
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.
Key Points:
- SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.
